PHASE III STUDY OF CHEMOHORMONAL THERAPY WITH TO DIFFERENT MODALITIES CONCOMITANT OR ALTERNATE VERSUS HORMONAL THERAPY ALONE IN ADVANCED PROSTATE CANCER PATIENTS.

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-003495-11-IT

Enrollment

200

Registered

2007-03-08

Start date

2005-03-16

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADVANCED PROSTATE CANCER MedDRA version: 6.1 Level: PT Classification code 10060862

Interventions

Trade Name: Taxotere Product Name: docetaxel Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: docetaxel CAS Number: 114977-28-5 Current Sponsor code: GOUP 01/2004 Conc

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026